Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.

ABSTRACT:

Introduction

The biological pathways involved in the preclinical stage of the Alzheimer's continuum are not well understood.

Methods

We used NeuroToolKit and Elecsys^® immunoassays to measure cerebrospinal fluid (CSF) amyloid-β (Aβ)42, Aβ40, phosphorylated tau (p-tau), total tau (t-tau), neurofilament light (NfL), neurogranin, sTREM2, YKL40, GFAP, IL6, S100, and α-synuclein in cognitively unimpaired participants of the ALFA+ study, many within the Alzheimer's continuum.

Results

CSF t-tau, p-tau, and neurogranin increase throughout aging only in Aβ-positive individuals, whereas NfL and glial biomarkers increase with aging regardless of Aβ status. We modelled biomarker changes as a function of CSF Aβ42/40, p-tau and p-tau/Aβ42 as proxies of disease progression

SUBMITTER: Mila-Aloma M 

PROVIDER: S-EPMC7586814 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature